Liverpool Skyline

Public Health Institute

Prof Harry Sumnall

Prof Harry Sumnall

Telephone: 0151 231 4516

Biography

Harry Sumnall is a Professor in Substance Use at the Public Health Institute. He is interested in all aspects of substance use, particularly young people’s health issues. Harry’s funded research programmes have examined the evidence base for substance misuse prevention and the mechanisms for implementing evidence based practice and policy.

Harry is a member of the UK Advisory Council on the Misuse of Drugs, a Board Member of the European Society for Prevention Research, a Trustee of the Drug and Alcohol prevention charity Mentor UK, and a scientific advisor to the MIND Foundation.

Degrees

2002, University of Liverpool, United Kingdom, PhD
1997, University of Manchester, United Kingdom, BSc

Academic appointments

Professor In Substance Use, Liverpool John Moores University, 2012 - present

Publications

Journal article

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. 2010. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review. Int J Drug Policy, 21 :335-342 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall H. 2009. Regulation of synthetic cannabinoids. Lancet, 374 :1595 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE guidance on ADHD. Diversion and abuse of methylphenidate in light of new guidance BMJ, 337 :a2287 >Link

Cole JC, Goudie AJ, Field M, Loverseed AC, Charlton S, Sumnall HR. 2008. The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 94 :183-190 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine withdrawal/discontinuation-induced hyperthermia in rats Prog.Neuropsychopharmacol.Biol.Psychiatry, 31 :1500-1503 >Link

Cole JC, Field M, Sumnall HR, Goudie AJ. 2007. Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole Behav.Pharmacol., 18 :185-190 >Link

Goudie AJ, Cooper GD, Cole JC, Sumnall HR. 2007. Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats J.Psychopharmacol., 21 :179-190 >Link

Goudie AJ, Sumnall HR, Field M, Clayton H, Cole JC. 2007. The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases Drug Alcohol Depend., 89 :107-115 >Link

Goudie AJ, Cole JC, Sumnall HR. 2007. Olanzapine and JL13 induce cross-tolerance to the clozapine discriminative stimulus in rats Behav.Pharmacol., 18 :9-17 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Field M, Santarcangelo M, Sumnall H, Goudie A, Cole J. 2006. Delay discounting and the behavioural economics of cigarette purchases in smokers: the effects of nicotine deprivation. Psychopharmacology (Berl), 186 :255-263 >DOI >Link

Sumnall HR, Cole JC, Jerome L. 2006. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy J.Psychopharmacol., 20 :670-682 >Link

Cole JC, Michailidou K, Jerome L, Sumnall HR. 2006. The effects of stereotype threat on cognitive function in ecstasy users J.Psychopharmacol., 20 :518-525 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Cole JC. 2005. Self-reported depressive symptomatology in community samples of polysubstance misusers who report Ecstasy use: a meta-analysis J.Psychopharmacol., 19 :84-92 >Link

Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. 2005. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs J.Psychopharmacol., 19 :67-70 >Link

Gamma A, Jerome L, Liechti ME, Sumnall HR. 2005. Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend., 77 :185-193 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Sumnall HR, Tyler E, Wagstaff GF, Cole JC. 2004. A behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers Drug Alcohol Depend., 76 :93-99 >Link

Sumnall HR, Wagstaff GF, Cole JC. 2004. Self-reported psychopathology in polydrug users J.Psychopharmacol., 18 :75-82 >Link

Sumnall HR, O'Shea E, Marsden CA, Cole JC. 2004. The effects of MDMA pretreatment on the behavioural effects of other drugs of abuse in the rat elevated plus-maze test Pharmacol.Biochem.Behav., 77 :805-814 >Link

Sumnall HR, Jerome L, Doblin R, Mithoefer MC. 2004. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450 Psychopharmacology (Berl), 171 :229-230 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole JC, Sumnall HR. 2003. The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) Neurosci.Biobehav.Rev., 27 :199-217 >Link

Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy Pharmacol.Ther., 98 :35-58 >Link

Cole JC, Sumnall HR, O'Shea E, Marsden CA. 2003. Effects of MDMA exposure on the conditioned place preference produced by other drugs of abuse Psychopharmacology (Berl), 166 :383-390 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Cole J, Sumnall H, Grob C. 2002. Where are the casualties? Response PSYCHOLOGIST, 15 :474-474 >Link

Editorial/letter to the editor

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Sumnall HR, Woolfall K, Cole J, Mackridge A, McVeigh J. 2008. NICE GUIDANCE ON ADHD Diversion and abuse of methylphenidate BMJ-BRITISH MEDICAL JOURNAL, 337 >DOI >Link

Conference publication

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Cole J, Bailey M, Sumnall H, King L. 2002. The content of ecstasy tablets: Implications for their long-term effects JOURNAL OF PSYCHOPHARMACOLOGY, Summer Meeting of the British-Association-for-Psychopharmacology 16 :A60-A60 >Link

Engagement & Impact

Editorial boards:

Addictive Behaviors

Addictive Behaviors

External committees:

Advisory Council on the Misuse of Drugs (ACMD), Home Office, Member, https://www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs

European Society for Prevention Research (EUSPR), EUSPR, Board member

Advisory Council on the Misuse of Drugs (ACMD), Home Office, Member, https://www.gov.uk/government/organisations/advisory-council-on-the-misuse-of-drugs

European Society for Prevention Research (EUSPR), EUSPR, Board member

External PGR Supervision - completed students:

University of Liverpool, PhD, Risk and protection in Northern Irish alcohol users

University of Liverpool, PhD, Risk and protection in Northern Irish alcohol users

Research Grants Awarded:

National Institute for Health and Care Excellence, NICE Evidence Review (economic modelling) : drug prevention, Grant value (£): 60000

Tameside Council, Needs Assessment of New Psychoactive Substance Use (Tameside Council, Grant value (£): 20000

ESRC, ESRC Seminar Series on New Psychoactive Substances/Human Enhancement Drugs, Grant value (£): 20000

Alcohol Research UK, Constructing alcohol identities. How young people navigate and make sense of online intoxicogenic marketing and culture, Grant value (£): 58000

EC DG-Justice DPIP, Promoting Excellence in Drug Prevention in the EU, Grant value (£): 590956

NIHR-PH, SHAHRP and TATI alcohol misuse prevention programme (STAMPP): school based randomised controlled trial, Grant value (£): 1044370

Warrington DAAT, Public perceptions of drug use in Warrington, UK, Grant value (£): 15000

EU, ALICE-RAP: Adolescents as customers, Grant value (£): 225000

EMCDDA, Social reintegration and reduction of social exclusion of drug users – Improving labour market participation of drug users in treatment, Grant value (£): 10000

AERC, European School Survey Project on Alcohol and Other Drugs; UK survey 2011, Grant value (£): 36000

EU-DPIP, European Family Empowerment: Improving family skills to prevent alcohol and drug related problems, Grant value (£): 396000

JRF, Influence of media on transmission of drinking cultures in young people, Grant value (£): 100000

NICE, Review of effectiveness and cost effectiveness of PSHE, Grant value (£): 99000

NICE, Fieldwork to inform NICE guidance on prevention of alcohol use disorders, Grant value (£): 35000

Wirral PCT, R&D Needs Assessment in Wirral PCT, Grant value (£): 20000

Liverpool, Sefton, and Salford PCTs, Health Needs Assessment in NW Prisons, Grant value (£): 35000

CHAMPS, Behavioural change interventions in Cheshire and Merseyside, Grant value (£): 25000

EU Public Health Executive Agency, EU Standards in Drug prevention, Grant value (£): 284507

NICE, Fieldwork to inform NICE guidance on optimum provision of NSPs, Grant value (£): 35000

Roy Castle Foundation, Qualitative evaluation of service users experiences of community smoking cessation programmes, Grant value (£): 15000

Cheshire DAAT, Young people substance use needs assessment, Grant value (£): 10000

National Institute for Health and Care Excellence, NICE Evidence Review (economic modelling) : drug prevention, Grant value (£): 60000

Tameside Council, Needs Assessment of New Psychoactive Substance Use (Tameside Council, Grant value (£): 20000

ESRC, ESRC Seminar Series on New Psychoactive Substances/Human Enhancement Drugs, Grant value (£): 20000

Alcohol Research UK, Constructing alcohol identities. How young people navigate and make sense of online intoxicogenic marketing and culture, Grant value (£): 58000

EC DG-Justice DPIP, Promoting Excellence in Drug Prevention in the EU, Grant value (£): 590956

NIHR-PH, SHAHRP and TATI alcohol misuse prevention programme (STAMPP): school based randomised controlled trial, Grant value (£): 1044370

Warrington DAAT, Public perceptions of drug use in Warrington, UK, Grant value (£): 15000

EU, ALICE-RAP: Adolescents as customers, Grant value (£): 225000

EMCDDA, Social reintegration and reduction of social exclusion of drug users – Improving labour market participation of drug users in treatment, Grant value (£): 10000

AERC, European School Survey Project on Alcohol and Other Drugs; UK survey 2011, Grant value (£): 36000

EU-DPIP, European Family Empowerment: Improving family skills to prevent alcohol and drug related problems, Grant value (£): 396000

JRF, Influence of media on transmission of drinking cultures in young people, Grant value (£): 100000

NICE, Review of effectiveness and cost effectiveness of PSHE, Grant value (£): 99000

NICE, Fieldwork to inform NICE guidance on prevention of alcohol use disorders, Grant value (£): 35000

Wirral PCT, R&D Needs Assessment in Wirral PCT, Grant value (£): 20000

Liverpool, Sefton, and Salford PCTs, Health Needs Assessment in NW Prisons, Grant value (£): 35000

CHAMPS, Behavioural change interventions in Cheshire and Merseyside, Grant value (£): 25000

EU Public Health Executive Agency, EU Standards in Drug prevention, Grant value (£): 284507

NICE, Fieldwork to inform NICE guidance on optimum provision of NSPs, Grant value (£): 35000

Roy Castle Foundation, Qualitative evaluation of service users experiences of community smoking cessation programmes, Grant value (£): 15000

Cheshire DAAT, Young people substance use needs assessment, Grant value (£): 10000